Omeros Corporation (OMER)
-NasdaqGM 5.08 
0.14(2.83%) May 23, 4:00PM EDT
| Prev Close: | 4.94 |
|---|
| Open: | 5.20 |
|---|
| Bid: | 4.22 x 500 |
|---|
| Ask: | 5.75 x 200 |
|---|
| 1y Target Est: | 15.63 |
|---|
| Beta: | 0.33 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 4.95 - 5.26 |
|---|
| 52wk Range: | 3.65 - 13.45 |
|---|
| Volume: | 303,442 |
|---|
| Avg Vol (3m): | 248,617 |
|---|
| Market Cap: | 131.71M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.60 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Omeros prepares for two studies of OMS824AP(Thu, May 23)
- Omeros announces investigational NDA cleared by FDA for OMS824theflyonthewall.com(Thu, May 23)
- InPlay: Omeros announces its IND to evaluate OMS824 in Huntington's disease has been cleared by the FDABriefing.com(Thu, May 23)
- Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's DiseasePR Newswire(Thu, May 23)
- Omeros to Present at Two Upcoming ConferencesPR Newswire(Wed, May 22)
- OMEROS CORP FinancialsEDGAR Online Financials(Fri, May 17)
- Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common StockPR Newswire(Tue, May 14)
- Investors are Digesting These Healthcare Stock Earnings Insightsat Wall St. Cheat Sheet(Sun, May 12)
- Short Interest Jumps 41.2% For OMERat TheStreet(Fri, May 10)
- OMEROS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and ExEDGAR Online(Fri, May 10)
- Omeros Corporation Reports First Quarter 2013 Financial ResultsPR Newswire(Fri, May 10)
- Omeros Announces $16.2 Million Registered Direct Offering of Common StockPR Newswire(Thu, May 9)
- Omeros Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Thu, May 9)
- OMEROS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Omeros requests fast track designation for OMS824theflyonthewall.com(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 22.79 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.50 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.39 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | -0.04 |
|---|
Business Summary
Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system.
View More